Skip to main content

Michael Ehrenstein, MD

Michael Ehrenstein, MD

Professor of Rheumatology
University College Hospital
University College of London School of Medicine
London, UK

Related Videos

Do you modify your dose of IL-6 inhibitor if you encounter elevations in LDL level?

Do you modify your dose of IL-6 inhibitor if you encounter elevations in LDL level?

Do you modify your dose of IL-6 inhibitor if you encounter elevations in LDL level?

Can we use biomarkers in any way to help align therapy in RA with a specific therapeutic agent?

Can we use biomarkers in any way to help align therapy in RA with a specific therapeutic agent?

Can we use biomarkers in any way to help align therapy in RA with a specific therapeutic agent?

Are there markers in RA that suggest a more progressive or aggressive disease course or that will predict non-responsiveness?

Are there markers in RA that suggest a more progressive or aggressive disease course or that will predict non-responsiveness?

Are there markers in RA that suggest a more progressive or aggressive disease course or that will predict non-responsiveness?

What percentage of patients who have had an inadequate response to an initial biologic agent such as TNF seem to respond to biologics with a different MOA, such as an IL-6 inhibitor?

What percentage of patients who have had an inadequate response to an initial biologic agent such as TNF seem to respond to biologics with a different MOA, such as an IL-6 inhibitor?

What percentage of patients who have had an inadequate response to an initial biologic agent such as TNF seem to respond to biologics with a different MOA, such as an IL-6 inhibitor?

How does one optimize the safety profile of IL-6 inhibitors?

How does one optimize the safety profile of IL-6 inhibitors?

How do TNFIs and IL-6 inhibitors compare as far as their effectiveness when used as monotherapy?

How do TNFIs and IL-6 inhibitors compare as far as their effectiveness when used as monotherapy?

How do TNFIs and IL-6 inhibitors compare as far as their effectiveness when used as monotherapy?

Why has IL-6 emerged as an important target for treating RA and through what mechanisms does inhibition of IL-6 affect the pathogenesis of RA?

Why has IL-6 emerged as an important target for treating RA and through what mechanisms does inhibition of IL-6 affect the pathogenesis of RA?

Why has IL-6 emerged as an important target for treating RA and through what mechanisms does inhibition of IL-6 affect the pathogenesis of RA?

When are you inclined to use combination therapy with a DMARD and biologic, and when is monotherapy with a DMARD alone a reasonable strategy?

When are you inclined to use combination therapy with a DMARD and biologic, and when is monotherapy with a DMARD alone a reasonable strategy?

When are you inclined to use combination therapy with a DMARD and biologic, and when is monotherapy with a DMARD alone a reasonable strategy?